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1. Introduction 
The antitumoral anthracycline antibiotic doxoru- 
bicin (adriamycin) has cardiotoxic side effects that 
have been related to disturbances in the intracellular 
metabolism of Ca’+. A number of authors have report- 
ed alterations in mitochondrial Ca2+ transport in heart, 
ranging from inhibition of uptake by mitochondria 
upon exposure to doxorubicin in vitro [ 1,2] to stim- 
ulation of uptake in rabbits chronically intoxicated 
with the antibiotic [3]. Substantial inhibitory effects 
on mitochondrial Ca2+ uptake were seen at concen- 
trations of doxorubicin in excess of 100 PM, and were 
not seen, or seen only at extremely high concentra- 
tions of the antibiotic, when the process was energized 
by ATP. The other Ca’+ transporting intracellular 
organelle in heart, the sarcoplasmic reticulum, was 
not affected by doxorubicin [I]. In heart cells, Ca2+ 
fluxes are controlled also by two plasma membrane 
(sarcolemma) pumping systems, a specific ATPase 
[4], and a Na+/Ca’+ exchange system [5,6]. The Ca’+ 
disturbances induced by doxorubicin could thus con- 
ceivably be mediated (also) by the impairment of 
either one ofthese two pumping functions, or of both. 
The involvement of sarcolemma is indicated by the 
finding [7] of reduced exchangeability of Ca2+ in 
doxorubicin-treated isolated guinea pig atria. In the 
present article, we wish to report on the inhibition of 
the Na+/Ca2+ exchange in isolated dog heart sarcolem- 
ma1 vesicles by low concentrations of doxorubicin. 
The finding may have important pharmacological im- 
plications, and opens new possibilities in the study of 
the Na+/Ca’+ exchanger. Doxorubicin is the first 
known specific inhibitor of this exchange system. 
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2. Materials and methods 
Dog heart sarcolemmal vesicles were prepared by a 
slight modification [8] of the procedure of Jones et 
al. [9]. After suspension in 160 mM NaCl, 20 mM 
Hepes, pH 7.4 (Na-medium) at a protein concentra- 
tion of approximately 5 mg m-’ , the vesicles were 
immediately frozen in liquid nitrogen and stored at 
-80°C. The vesicle preparations were routinely enriched 
about 100 fold in sarcolemmal markers as compared 
to the initial homogenate. Ca2’ transport was measured 
either with the Ca*+-sensitive dye Arsenazo II1 [lo] 
monitored at 685-660 nm in an Aminco DW-2 spec- 
trophotometer (mitochondrial Ca*’ fluxes [ 1 I] and 
sarcolemmal Na+/Ca2+ exchange [S]), or isotopically 
(ATP-supported Ca’+-pump in heart sarcolcmma [4]). 
Control experiments showed that the response of 
Arsenazo III to [Ca2+]changes was not altered by the 
addition of doxorubicin up to a concentration of 
100 PM. When Ca2+ binding to the sarcolemmal vesi- 
cles was measured, KCI-preloaded sarcolemmal vesicles 
were diluted in 160 mM KCI, 20 mM Hepes, 0.5 FM 
free 45Ca2+ at 37”C, and 100 pl-aliquots were subse- 
quently withdrawn and filtered (millipore filters, pore 
diameter: 0.22pm). The filters were washed with 2 ml 
of 160 mM TrisCl, pH 7.4 and then assayed for 
45Ca2+ radioactivity. 
Arsenazo III was obtained from Fluka AC, Buchs, 
Switzerland. Valinomycin was from Sigma. Doxorubi- 
tin and its 4’-epimer were obtained from Farmitalia, 
Milano, Italy and dissolved in H20. The solutions 
were prepared on the day of the experiment, and pro- 
tected from light. 
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3. Results and discussion 
A number of experiments performed on isolated 
heart mitochondria have failed to detect significant 
alterations of either the uptake of Ca2+ or of its Na’- 
induced release, in the presence of concentrations of 
doxorubicin ranging between 5 and 80 PM. In the 
same concentration range doxorubicin had no effect 
on the Ca’+-pumping ATPase of the plasma membrane 
and on the associated Ca2+ uptake, indicating that the 
drug did not alter the passive permeability of the sar- 
colemmal membrane. By contrast, it depressed very 
markedly the initial velocity of the sarcolemmal Na’/ 
CaZf exchange, 5% inhibition being observed at 10pM. 
At 40 PM, the inhibition reached 8% (table 1, and 
fig.l). The inhibition was not prevented by increasing 
the external level of free Ca2+, indicating that the 
inhibition was not of the competitive type. One inter- 
esting derivative of doxorubicin is the 4’epimer, which 
has proven to be less cardiotoxic in vivo, and in cells 
grown in vitro [ 121, than the parent compound. Table 
1 shows that the 4’-epimer has a less evident inhibitory 
effect on the Na+/Ca’+ exchange. 
It was of interest to study whether the inhibition 
reflected the (tight) binding of doxorubicin to the 
exchanger, or to the membrane domain surrounding 
Table 1 
Effect of doxorubicin and of its 4’epiderivative on Ca*+ 
influx into heart sarcolemmal vesicles through the Na+/Ca’+ 
exchanger 
- 
Additions Initial rate of Ca*+ uptake 
(nmol Ca’+ per mg protein per s) 
None 9.8 100% 
Doxorubicin 
5 IJM 
10/.1M 
20 /.IM 
40 /LM 
80 FM 
7.9 80.6% 
4.2 42.8% 
2.5 25.5% 
1.8 18.3% 
1.5 15.3% 
4’epidoxorubicin 
10 /.LM 
20 /.LM 
40 PM 
9.5 96.9% 
5.1 52.0% 
3.9 39.8% 
Experimental conditions as in fig.1. The initial rate is defined 
as the rate of Ca*+ uptake during the first 2 s after the dilu- 
tion of the vesicles in the KCl-medium. ‘Ihe values were cor- 
rected for non-specific binding by subtraction of the Ca’+ 
associated to the vesicles diluted in the Na-medium 
J 
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Fig.1. Initial rate of Ca2+ uptake on the Nd/Ca*’ exchanger. 
Technical details in the Materials and methods section and in 
Caroni et al. [8]. Free Ca*+, 0.5 WM . 5~1 of vesicles in Na- 
medium (50 pg of protein) diluted at arrow in 1 ml of 160 mM 
KCl, 20 mM Hepes, 1 PM valinomycin, 50 PM Arsenazo III, 
pH 7.4, 37°C. 1:control; 2:lO UM doxorubicin added to the 
reaction medium; 3:50 PM doxorubicin added to the reac- 
tion medium. 
it, or a labile association. The experiment described in 
table 2 indicates that the association must be rather 
tight, since the inhibition was still clearly evident, 
albeit reduced, in sarcolemmal preparations that had 
been pre-incubated with doxorubicin, and then diluted 
200 times in a medium not containing it. 
As mentioned, one of us [7] has recently reported 
that doxorubicin reduces the exchangeability of Ca2+ 
Table 2 
The sodium calcium exchange in heart sarcolemmal vesicles 
preincubated with doxorubicin 
Preincubation with Initial rate 
(nmoles Cal+ per mg protein per s) 
No addition 9.8 
Doxorubicin 
10 /.LM 6.9 
20 PM 5.9 
40 /.iM 5.4 
Preincubation of the vesicles for 10 min at 37°C with the 
concentrations of doxorubicin indicated, then dilution 200 X 
in a medium containing no doxorubicin and 0.5 PM free Ca’+. 
Other experimental conditions as in [8] and in table 1 
185 
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in isolated atria. In principle, the observation could 
be due to effects of doxorubicin not related to influ- 
ences on the Ca2+ transporting membrane systems. 
One possibility is the direct influence of doxorubicin 
on the Ca’+ non-specifically associated with the sar- 
colemmal membrane [ 131. To test it, sarcolemmal 
vesicles were exposed to 0.5 PM 45CaC12 in the pres- 
ence or in the absence of doxorubicin. Energy sources 
(ATP, Na’ gradient) were not provided, so that only 
the external side of the sarcolemmal membrane could 
have become labeled. As control, 0.5 mM La3+, which 
is known to displace Ca2+ from non specific binding 
sites in membranes, was used. The amount of 45Ca2+ 
bound to the membranes was not altered by doxoru- 
bicin, but was markedly decreased, as expected, by 
La3+. A second alternative possibility would be the 
decrease of the free Ca2’ concentration by doxorubi- 
tin. Gosalves et al [ 141 have claimed that the effect 
of doxorubicin on heart might be related to its Ca” 
chelating properties. However, Gosalves et al. [ 141 
have employed mM concentration of Ca2+, whereas in 
the present experimental conditions (0.5 PM Ca2’ 
free) doxorubicin failed to influence the free Ca2+ 
concentration in a concentration range where it inhib- 
its the Na+/Ca’+ exchange up to 80%. The decreased 
exchangeability of Ca2+ induced by doxorubicin must 
therefore be explained differently, and it appears per- 
missible to relate it to the effects on the Na+/Ca2+ ex- 
changer reported in the present paper. Indeed, the 
transmembrane exchange of Ca2+ is the result of the 
combined functioning of the influx and efflux pro- 
cesses. It requires the entry of Ca2’ through the slow 
Ca2+ channel (and, possibly, through the Na+/Ca2+ 
exchanger) and its ejection via the specific pumping 
ATPase and through the Na+/Ca’+ exchanger. The lat- 
ter system, therefore, represents an essential compo- 
nent of the ‘cycling’ of Ca” across the sarcolemmal 
membrane, and it is evident that its inhibition will lead 
to a decreased ‘exchangeability’ of Ca2+ between heart 
sarcoplasm and medium. 
Whether doxorubicin, in exerting its inhibition, 
interacts directly with the Na’/Ca2+ exchanger is an 
open question. The above mentioned persistence of 
measurable inhibition in membranes diluted after 
doxorubicin preincubation in solutions essentially 
free of the inhibitor indicates tight binding, but offers 
no clues as to the nature of the site of interaction. 
The recent observation by Goormaghtigh et al. [15] 
that the inhibitor interacts specifically and with high 
186 
affinity with acidic phospholipids, as well as earlier 
indications for the interaction of doxorubicin with 
phospholipids [ 13,161, may be relevant to this point. 
Although doxorubicin under the experimental condi- 
tions of the present study does not displace the Ca2+ 
bound to sarcolemma, its interaction with acidic phos- 
pholipids in the environment surrounding the ex- 
changer may possibly hinder its function. 
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